For patients with ulcerative colitis, upadacitinib is associated with improved disease-specific outcomes compared with tofacitinib.
The Swiss drugmaker announced the global phase 3 SOLAR-1 trial evaluating the alpha-specific PI3K inhibitor codenamed BYL719 (alpelisib) has met the primary target and improved progression-free ...
Our updated analyses presented at SABCS show STX-478’s low dose modification rates and increased response rate at higher doses, reflecting its high level of pathway inhibition. These studies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback